The Mannan Binding Lectin Serine Protease 2 pipeline drugs market research report outlays comprehensive information on the Mannan Binding Lectin Serine Protease 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Mannan Binding Lectin Serine Protease 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Genito Urinary System, Cardiovascular, Immunology, and Central Nervous System which include the indications IgA Nephropathy (Berger’s Disease), Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Ischemia Reperfusion Injury, Thrombotic Microangiopathy, Lupus Nephritis, Unspecified Immunological Disorders, and Diabetic Neuropathy. It also reviews key players involved in Mannan Binding Lectin Serine Protease 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Mannan Binding Lectin Serine Protease 2 pipeline targets constitutes close to 14 molecules. Out of which, approximately 14 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Filing rejected/ Withdrawn, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 2, 1, 1, 8, and 1 respectively.
Mannan Binding Lectin Serine Protease 2 overview
Mannan-binding lectin serine protease 2 (MASP2) is a serum protease that plays an important role in the activation of the complement system via mannose-binding lectin. After activation by auto-catalytic cleavage it cleaves C2 and C4, leading to their activation and to the formation of C3 convertase.
For a complete picture of Mannan Binding Lectin Serine Protease 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
